亨廷顿病Q175小鼠模型中mGluR5的纵向特征:11C-ABP688 PET显像研究
研究采用11C-ABP688 PET/CT对18只杂合子Q175小鼠和18只野生型同窝小鼠在6、9、13月龄进行纵向显像,并用小脑为参考区计算纹状体和皮质的不可置换结合电位(BPND)。杂合子小鼠各时间点纹状体和皮质BPND均显著低于野生型,且13月龄较6月龄纹状体BPND降低;离体分析证实纹状体和皮质mGluR5降低而神经元密度无差异。作者认为11C-ABP688 PET显像可能是监测亨廷顿病进展和治疗策略的潜在生物标志物。
要点
- 杂合子小鼠纹状体BPND在6、9、13月龄分别较野生型降低13.1%、13.5%、14.2%(均P<0.001)。
- 杂合子小鼠皮质BPND在6、9、13月龄分别较野生型降低9.8%、10.2%、10.6%(均P<0.01)。
- 杂合子小鼠13月龄较6月龄纹状体BPND降低10.4%(P<0.05)。
核心结论
- 11C-ABP688 PET/CT显像显示杂合子小鼠纹状体和皮质配体结合较野生型明显降低,并呈时间性下降。
- 作者认为11C-ABP688 PET显像可能是监测亨廷顿病进展和治疗策略的潜在生物标志物。
研究设计与样本
- 研究对18只杂合子小鼠和18只野生型同窝小鼠在6、9、13月龄三个时间点行11C-ABP688 PET显像,随后行CT扫描。
- 以小脑为参考区计算纹状体和皮质的11C-ABP688不可置换结合电位(BPND)。
- 对BPND图像进行基于体素的统计参数映射(SPM)分析。
- 对6月龄小鼠行离体验证mGluR5水平和神经元密度。
主要发现
- 杂合子小鼠纹状体BPND在6、9、13月龄分别较野生型降低13.1%、13.5%、14.2%(均P<0.001)。
- 杂合子小鼠皮质BPND在6、9、13月龄分别较野生型降低9.8%、10.2%、10.6%(均P<0.01)。
- 杂合子小鼠纹状体BPND 13月龄较6月龄降低10.4%(P<0.05)。
- SPM分析证实杂合子小鼠较野生型BPND降低,并显示杂合子小鼠纹状体11C-ABP688结合随时间下降。
- 离体分析证实杂合子小鼠纹状体mGluR5降低36.6%(P<0.01)、皮质降低16.6%(P<0.05),神经元密度无差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Metabotropic glutamate receptor 5 (mGluR5) represents a potential therapeutic target for Huntington disease. Using 11C-ABP688 (3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone-O-11C-methyl-oxime), a noncompetitive and highly selective antagonist for mGluR5, we aimed to longitudinally characterize in vivo changes in mGluR5 by means of PET imaging in the Q175 mouse model of Huntington disease. Methods:11C-ABP688 PET imaging, followed by a CT scan, was performed on 18 heterozygous mice and 18 wild-type (WT) littermates at 3 different time points (6, 9, and 13 mo old). 11C-ABP688 nondisplaceable binding potential (BPND) was calculated for each time point in striatum and cortex using the cerebellum as the reference region. In addition, voxel-based statistical parametric mapping (SPM) analysis was performed on BPND images. Postmortem validation of mGluR5 level and neuronal density was performed on the mice at 6 mo old. Results: The 11C-ABP688 BPND of heterozygous animals was significantly reduced at all time points in the striatum (-13.1%, -13.5%, and -14.2% at 6, 9, and 13 mo, respectively; P < 0.001 for all) and in the cortex (-9.8%, -10.2%, and -10.6%, respectively; P < 0.01 for all), when compared with WT animals. Longitudinal changes in 11C-ABP688 BPND were also found in heterozygous mice, showing a reduction at 13 mo compared with 6 mo (-10.4%, P < 0.05). SPM analysis confirmed reduced BPND in heterozygous compared with WT mice, as well as a time-related decline in 11C-ABP688 binding in the striatum of heterozygous mice. Postmortem analysis confirmed a mGluR5 decrease in both striatum (-36.6%; P < 0.01) and cortex (-16.6%; P < 0.05) in heterozygous mice, whereas no difference in neuronal density was found. Conclusion: In vivo imaging of mGluR5 using 11C-ABP688 PET/CT revealed a marked reduction in ligand binding in the striatum and cortex of heterozygous mice, compared with WT mice, as well as a temporal decline. This study suggests that 11C-ABP688 PET imaging is a potential biomarker to monitor the progression of, and therapeutic strategies for, Huntington disease.
引用
- Bertoglio D, Kosten L, Verhaeghe J, et al. Longitudinal Characterization of mGluR5 Using 11C-ABP688 PET Imaging in the Q175 Mouse Model of Huntington Disease. J Nucl Med. 2018. PMID: 29794227. doi:10.2967/jnumed.118.210658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。